Trial
NCT01907815
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Recurrent Adult Acute Myeloid Leukemia
Intervention
Akt Inhibitor GSK2141795
Why stopped
Lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-06